Agnieszka Brożyna

Agnieszka Brożyna

*This is an algorithmically generated author record based on publicly available information.

Agnieszka Brożyna has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience

    by Iwona Malinowska, Michal Romiszewski, Katarzyna Smalisz, Anna Stelmaszczyk - Emmel, Barbara Nasilowska - Adamska, Malgorzata Krol, Elzbieta Urbanowska, Agnieszka Brozyna, Bozenna Baginska - Dembowska


  • Open Access

    Health Status in Long-Term Survivors of Hepatoblastoma

    by Bożenna Dembowska-Bagińska, Jolanta Więckowska, Agnieszka Brożyna, Ewa Święszkowska, Hor Ismail, Dorota Broniszczak-Czyszek, Marek Stefanowicz, Wiesława Grajkowska, Piotr Kaliciński

    The aim of this study was to evaluate the health status of children cured from hepatoblastoma. Forty-five patients with hepatoblastoma treated between 1996–2014 were assessed. The recorded data included sex, age at diagnosis, disease stage, treatment methods, time since diagnosis, and the evaluation of health status domains which included performance status, growth development, hearing, cardiovascular, skeletal, gastrointestinal, genitourinary, neurological, and hematological function. There were 30 boys and 15 girls. The age at diagnosis ranged from one month to 14 years (median one year). At the time of the health status evaluation, the youngest patient was 5.5 years old and the oldest was 21 years of age (median—10 years). All patients were treated according to the Childhood Liver Tumors Strategy Group—SIOPEL recommendations, though they were not active participants of the studies. The median cumulative dose of cisplatin was 520 mg/m2 and 360 mg/m2 for doxorubicin. Thirty-six patients underwent partial hepatectomy, and nine total hepatectomy and liver transplantation. At a median of nine years from diagnosis, 68% of hepatoblastoma survivors had experienced at least one chronic health condition of any grade. The most frequent late complication was ototoxicity (28.8%), and the most serious were second malignancies (6.6%) and cardiomyopathy (4.4%). Conclusion: Survivors of hepatoblastoma are at risk for long-term complications. They require long-term monitoring for late effects.


  • Dental Caries in Children and Adolescents During and After Antineoplastic Chemotherapy

    by Dorota Olczak-Kowalczyk, Ewa Krasuska-Sławińska, Agnieszka Brożyna, Anna Turska-Szybka, Bożenna Dembowska-Bagińska

    Objective: To assess caries incidence, intensity, and treatment in children and adolescents under/after antineoplastic treatment. Study design: Patients with permanent and mixed dentition were divided into three groups of 60 patients each (5–18 years): CH – under chemotherapy; PCH – after chemotherapy; CG – generally healthy subjects. Caries incidence, intensity (DMFT/dmft, DMFS/dmfs), and mean numbers of teeth/surfaces with white spot lesions–WSL (D1+2/d1+2) were assessed following the ICDAS-II criteria. Statistical analysis: Mann-Whitney U test, significance at p≤0.05). Results: Caries incidence was significantly higher in PCH and CH (88.33% and 90%) than in CG (66.66%). Caries intensity was higher in both mixed and permanent dentition in patients under and after chemotherapy. The DMFS/DMFT correlation was the highest in PCH. Treatment indexes for primary and permanent teeth treatment were significantly lower in PCH and CH than CG. Conclusion: Antineoplastic chemotherapy is associated with caries development and its high incidence during/after treatment. As dental hygiene was poor in patients under and after antineoplastic treatment, dental checkups need to be more frequent and thorough.


  • Open Access

    Changes in the chemical composition of mineralised teeth in children after antineoplastic treatment

    by Ewa Krasuska-Sławińska, Bożenna Dembowska-Bagińska, Agnieszka Brożyna, Dorota Olczak-Kowalczyk, Elżbieta Czarnowska, Agnieszka Sowińska

    Introduction: Chemotherapy, neoplasms, and their complications linked to malabsorption, malnutrition, and metabolic disorders may lead to improper tooth development and frequent severe caries in patients during/after antineoplastic treatment and to a more frequent improper tooth development in patients undergoing chemotherapy during odontogenesis. However, the causes of these abnormalities remain unknown; there are no studies on the impact of antineoplastic treatment and its complications on the chemical composition of mineralised teeth. Aim of the study: To compare the chemical composition of mineralised teeth extracted due to complicated caries in children after chemotherapy, and of teeth extracted due to orthodontic treatment in generally healthy children. Material and methods: The treatment group included five teeth extracted due to complicated caries in children after antineoplastic treatment. The control group included five teeth extracted due to orthodontic treatment in generally healthy children. The chemical composition of enamel, dentine, cementum, interior of the canal, and enamel abnormalities in teeth extracted from patients after chemotherapy and in generally healthy patients were assessed with energy-dispersive X-ray spectroscopy. Results were analysed statistically. Results: The magnesium (Mg) and zinc (Zn) mass contents in the enamel of patients after chemotherapy increased and so did the calcium (Ca) to phosphorus (P) ratio when compared to controls. Areas with abnormal enamel in patients after chemotherapy had lower concentrations of Ca and P, and higher concentrations of trace elements (Mg, Cl, and Na). The levels of the assessed elements in dentine, cementum, and inside the canal were similar in both groups of teeth.


  • Open Access

    Antineoplastic chemotherapy and congenital tooth abnormalities in children and adolescents

    by Ewa Krasuska-Sławińska, Agnieszka Brożyna, Bożenna Dembowska-Bagińska, Dorota Olczak-Kowalczyk

    Aim of the study : Chemotherapeutic treatment in children and adolescents carries a risk of congenital tooth disorders and dentinoma. Study objective is to assess the correlation between tooth abnormalities, early complications of multidrug chemotherapy, and chemotherapeutics used in different...


  • Congenital brain tumors in a series of 56 patients

    by Elżbieta Jurkiewicz, Agnieszka Brożyna, Wiesława Grajkowska, Monika Bekiesińska-Figatowska, Paweł Daszkiewicz, Katarzyna Nowak, Katarzyna Malczyk, Jerzy Walecki, Danuta Perek, Małgorzata Syczewska

    Central nervous system tumors diagnosed before the end of the first year of life differ from those found in older children and in adults. The differences include mode of clinical presentation, anatomical distribution, histopathological diagnoses, response to therapy, and outcome.


    • 21 April 2012
      • Vol. 15  (4) , 458-61

    Congenital intramedullary spinal cord tumours: a report of two cases.

    by Anna Sobieniecka, Elżbieta Jurkiewicz, Justyna Czech-Kowalska, Monika Bekiesińska-Figatowska, Wiesława Grajkowska, Bożenna Dembowska-Bagińska, Agnieszka Brozyna, Anna Dobrzanska, Danuta Perek, Katarzyna Nowak, et al.

    We present two different cases of congenital intramedullary tumours, one of a patient in whom treatment was started without pathological confirmation of a malignant tumour and the other of a primitive neuroectodermal tumour. Magnetic resonance imaging is the most useful tool in the diagnosis of malignant intramedullary tumours and differentiation from other types of spinal cord lesions.

  • Non‐Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS)

    by Bozenna Dembowska‐Baginska, Danuta Perek, Agnieszka Brozyna, Anna Wakulinska, Dorota Olczak‐Kowalczyk, Malgorzata Gladkowska‐Dura, Wieslawa Grajkowska, Krystyna H. Chrzanowska

    Background: Due to small number of patients with Nijmegen Breakage Syndrome (NBS) and Non‐Hodgkin lymphoma (NHL) experience in their treatment is limited.Procedure: Since 1996, 17 patients with a median age of 9.5 years who had NBS, were treated for NHL. NHL type, stage, chemotherapy, dose modifications, chemotherapy delays, response to chemotherapy, toxicity, outcome and correlation of drug reduction with response to treatment and outcome were analyzed.Results: Nine patients had TNHL, eight BNHL. TNHL patients received BFM and BNHL LMB type protocols. Doses of cytostatics were reduced in the first chemotherapy courses. Further modifications depended on severity of complications. None of the patients complied with timing of chemotherapy. Complete remissions after induction were achieved in 8 of 9 TNHL and 3 out 8 of BNHL patients. All patients experienced grade 4 toxicities. Two patients died from complications. Six of 17 patients are alive. All received more than 80% of recommended doses of chemotherapy. No differences in the type, number of responses or grade 3 and 4 toxicities between patients receiving less or more than 80% of drug doses were observed. Treatment related deaths concerned patients who received less than 80% of drug doses.Conclusions: Patients with NBS develop both T and B cell lymphomas. Treatment outcome is poor and might be improved by administering over 80% of drug doses. Although toxicity often depends upon drug doses, our patients experienced equal grade 3 and 4 toxicities whether they received more or less than 80% of the chemotherapeutic agents. Pediatr Blood Cancer 2009;52:186–190.


    • 1 January 2007
      • Vol. 45  (1) , 1-8

    Clinicopathological considerations on angiogenic potential in neuroblastoma Schwannian stroma - poor tumours.

    by Ewa Izycka-Swieszewska, Elzbieta Drozyńska, Robert Rzepko, Bozena Dembowska, Wiesława Grajkowska, Agnieszka Brozyna, Danuta Perek, Anna Balcerska, Kazimierz Jaśkiewicz

    The aim of the study was to determine microscopic angiogenic parameters of neuroblastoma (NB) Schwannian stroma-poor tumours. Furthermore the associations between vascular parameters and clinicopathological features of tumours and basic prognostic factors were analysed. Examined tissue samples from 62 NB came from 39 untreated and 23 chemotherapy pretreated tumours. The clinicopathological data comprised: patients' age, gender, survival, tumour site and stage, tumour histology and MYCN status.The morphological analysis of the angiogenic potential concentrated on examination of vascular patterns - classical type or pathological angiogenesis with mural microvascular proliferation (MVP). The quantitative study included semi-automatic assessment of vascular density (VD) in CD34 stained tumour sections. Pathologic angiogenesis with MVP, including simple and/or glomeruloid type, was encountered in 25 cases and was more frequent in differentiating histology subtype and extraadrenal tumours. VD value ranged from 56 to 385 vessels/mm2 (median 149). Higher VD was connected with younger patient's age. In untreated tumours VD was significantly higher in infants than in children over one year of age. Pathologic type angiogenesis and lower VD were found to be associated with shorter survival. Our study confirmed high vascularization of NB and revealed common occurrence of vascular pattern with MVP. Angiogenic potential in the analysed group showed diversity related to some clinicopathological tumour features. This points toward heterogeneity of NB tumours in vascular aspects, possibly affecting tumours' reactivity to antiangiogenic therapy.